Adrenergic Nerves and Noradrenaline in Lung Fibrosis
Official title: Adrenergic Nerves, Noradrenaline, and Myofibroblasts in Idiopathic Pulmonary Fibrosis
Funded at Yale University · NIH-11351083 · Data updated 2026-11-12
A physician-scientist-in-training at Yale seeks to build a patient-focused research program on how nerve signals and adrenaline affect lung scarring in IPF.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | July 5, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $165,564 |
| NIH project number | 1K08HL185896-01 |
| Project ID | NIH-11351083 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with IPF or related fibrotic lung conditions who may participate in future translational studies or donate samples for related research.
✕Less likely to help
This career development grant does not directly enroll patients in a specific trial today.
What this research studies
This grant supports a clinician-scientist’s career development to study the neurobiology of idiopathic pulmonary fibrosis using experimental models and mentors with expertise in adrenergic signaling, tissue remodeling, and genomics. The program emphasizes training, coursework, and a research plan that will establish independent work distinct from the mentor’s projects, with significant institutional support. The work aims to translate insights about adrenergic nerves and noradrenaline’s role in IPF toward future therapies for patients. The applicant will dedicate 75% effort to career development and research to become an independent, funded physician-scientist.
Why it matters
Potential benefit: If successful, patients with IPF could benefit from a better understanding of nerve-based drivers of fibrosis, potentially informing new treatment strategies.
How similar studies have gone: Prior work has shown adrenergic signaling can drive fibrosis in experimental lung models, supporting potential translational relevance.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Ishikawa, Genta — Yale University
- Study coordinator: Ishikawa, Genta
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.